Search 

Western Oncolytics is developing a novel immunotherapy to treat a wide range of solid tumors.  Our therapy is an oncolytic vector with multiple therapeutic transgenes that both stimulate the immune system and remove local tumor immune inhibition.  The vector is engineered to avoid the immune system itself, thus overcoming a major drawback in competing designs.  It is the only therapy in the world with these leading attributes.  Western Oncolytics' therapy works in combination with other treatments, e.g. checkpoint inhibitors, and is capable of systemic (intravenous) delivery. 

Our team comprises the leading scientists, clinicians, and regulatory experts within our field, including entrepreneurs who successfully exited companies with earlier technologies.  In comparison animal testing measuring tumor growth and survival, our therapy performed far better than earlier, clinically-proven oncolytic therapies.

Western Oncolytics is currently raising investment to complete preclinical development and a planned clinical trial. 

WuXi Venture Fund is the corporate venture arm of WuXi AppTec, a multinational CRO based in Shanghai China with multiple offices across China and the United States. The fund makes equity investments into technology and life science companies to enhance or leverage WuXi AppTec's platform capabilities. The investment size will be varied based on a case-by-case basis. The firm invests in life science companies across the globe with an emphasis in China and the US.

Xalud Therapeutics is developing novel, non-opioid therapies for the treatment of neuropathic pain and osteoarthritis. Our lead product, XT-101, has shown exceptional efficacy in the leading rodent models of pain and in canine patients with neuropathic pain and osteoarthritis. XT-101 has an excellent safety profile -- it does not cause sedation, dizziness, numbness, addiction or tolerance.  7 and 28 day GLP toxicology studies have been completed with excellent results.  Xalud intends to file an IND for a Phase I/IIa trial in mid-2015 and, pending funding, initiate clinical trials thereafter.

Xalud's approach to treating pain is fundamentally different than conventional approaches. XT-101 causes the body to produce the natural anti-inflammatory IL-10.  In neuropathic pain, the use of this broad spectrum anti-inflammatory reduces inflammation around the spinal cord and reduces aberant pain signaling.  In gold-standard rodent models, a single injection of XT-101 completely eliminates neuropathic pain for 12 weeks.  We have also tested XT-101 in canine patients with severe osteoarthritis that has been resistant to standard treatments.  In these patients, XT-101 has provided long lasting pain relief resulting in dramatically increased mobility and activity levels and increased joint flexibility.

To date, Xalud's efforts have been supported by over $6 million of grant funding from the NIH, the DOD, and disease foundations.  We seek to raise $6 to $10 Million to fund our initial clinical trial or trials.  These will be placebo controlled Phase I/IIa trials in actual patients.  Because XT-101 has an extended duration, we expect that these trials will provide the safety, efficacy and biomarker data necessary to support a robust Phase II program.